According to an investigation reported today at the 2011 European Multidisciplinary Cancer Congress, individuals suffering with bone metastases from advanced prostate cancer have not had many options until recently. Now the first Phase II investigation of an alpha-pharmaceutical in these individuals has revealed that it can extend survival considerably. Dr...
More...
More...